首页> 美国卫生研究院文献>Respiratory Research >Dose-finding evaluation of once-daily treatment with olodaterol a novel long-acting β2-agonist in patients with asthma: results of a parallel-group study and a crossover study

【2h】

Dose-finding evaluation of once-daily treatment with olodaterol a novel long-acting β2-agonist in patients with asthma: results of a parallel-group study and a crossover study

机译：新型长效β2受体激动剂奥洛他特尔每日一次治疗哮喘患者的剂量发现评估：平行研究和交叉研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundOlodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease.

机译：背景奥洛他特罗是一种新型的吸入型长效β2-激动剂（LABA），在哮喘和慢性阻塞性肺疾病中具有超过24小时的作用时间。

著录项

期刊名称 Respiratory Research
作者
Paul M. O’Byrne; Tony D’Urzo; Ekkehard Beck; Matjaž Fležar; Martina Gahlemann; Lorna Hart; Zuzana Blahova; Robert Toorawa; Kai-Michael Beeh;
展开▼
作者单位

展开▼
年(卷),期 2015(16),1
年度 2015
页码 97
总页数 11
原文格式 PDF
正文语种
中图分类呼吸生理学 ;
关键词
Olodaterol Asthma Long-acting β2-agonist Dose-finding;

机译：奥洛他特罗;哮喘;长效β2-激动剂;剂量确定;

相似文献

外文文献
中文文献
专利

1. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β₂-agonist, in patients with asthma: results of a parallel-group study and a crossover study [J] . Paul M. OByrne, Tony DUrzo, Ekkehard Beck, Respiratory Research . 2015 ,第1期

机译：新型长效β_{2 激动剂奥洛他特尔每日一次治疗哮喘患者的剂量发现评估：一项平行研究和一项交叉研究的结果}
2. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting beta(2)-agonist, in patients with chronic obstructive pulmonary disease [J] . Joos Guy F., Aumann Joseph-Leon, Coeck Carl, Respiratory medicine . 2015 ,第5期

机译：一项随机，双盲，四路，交叉试验，比较了慢性阻塞性肺病患者每天一次和每天两次用新型长效β（2）激动剂奥洛他特罗治疗的24小时FEV1曲线疾病
3. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study [J] . Ana R Sousa, John H Riley, Alison Church, Npj - Primary Care Respiratory Medicine . 2016 ,第8期

机译：乌米地丁对有症状COPD患者吸入皮质类固醇/长效β2-激动剂的影响：一项随机，双盲，平行分组研究
4. Once-daily Nadroparin Versus Twice-daily Nadroparin in the Treatment of Patients with Acute Coronary Syndromes: The SAFRAX Study [C] . V. Hricak, A. Leizorovic International Congress on Thrombosis . 2006

机译：每日一日奈多林与每次每日Nadroparin治疗患者急性冠状动脉综合征患者：Safrax研究
5. Two-stage continual reassessment method and patient heterogeneity for dose-finding studies. [D] . Jia, Xiaoyu. 2014

机译：两阶段连续重新评估方法和患者异质性用于剂量寻找研究。
6. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised double-blind parallel-group study [O] . Ana R Sousa, John H Riley, Alison Church, 2016

机译：乌米地丁对有症状COPD患者吸入皮质类固醇/长效β2-激动剂的影响：一项随机双盲平行分组研究
7. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. [O] . O'Byrne, Paul M, D'Urzo, Tony, Beck, Ekkehard, 2015

机译：用于哮喘患者的新型长效β2-激动剂奥达特罗每日一次治疗的剂量发现评估：平行组研究和交叉研究的结果。

Dose-finding evaluation of once-daily treatment with olodaterol a novel long-acting β2-agonist in patients with asthma: results of a parallel-group study and a crossover study

摘要

著录项

相似文献

相关主题

期刊订阅